NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative ...
Encellin, a biotechnology company pioneering Encapsulated Cell Replacement Therapy (ENCRT), today announced interim clinical results from its ongoing Phase 1 investigational trial (NCT06408311) in ...
On January 12, 2026, NewcelX Ltd. reported peer-reviewed positive results from an international collaborative study published in Diabetology, showing that engineered scaffolds incorporating ...
NEW YORK, USA, August 21, 2023/EINPresswire.com/ -- Altucell Therapeutics is making monumental advancements in the realm of diabetes care. The company remains at the ...
SAN FRANCISCO--(BUSINESS WIRE)--Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing ...
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) ...
Diabetes mellitus (DM) is a metabolic disease characterized by pancreatic malfunctional and poor production of insulin. Imagine your pancreas is a factory for insulin, a key hormone that keeps your ...
Islet Transplantation with Blood Vessel Cells Shows Promise to Treat Type 1 Diabetes Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the ...
Avant Technologies, Art-Islets, and Austrianova Announce Joint Venture to Advance Diabetes Treatment
LAS VEGAS, Sept. 24, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), a Nevada-based corporation, Art-Islets Pte. Ltd. ("Art ...
NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback